495 related articles for article (PubMed ID: 15261925)
1. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Goto S; Tamura N; Ishida H
J Am Coll Cardiol; 2004 Jul; 44(2):316-23. PubMed ID: 15261925
[TBL] [Abstract][Full Text] [Related]
2. [Different inhibiting effects of abciximab and tirofiban on platelet thrombus formation on a collagen surface under flow conditions].
Shimazaki T; Goto S; Sakakibara M; Eto K; Kim JY; Ichikawa N; Yoshida M; Nagaoka Y; Isshiki T; Handa S
J Cardiol; 2000 Aug; 36(2):113-21. PubMed ID: 10955255
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
5. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
[TBL] [Abstract][Full Text] [Related]
6. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling.
Goto S; Tamura N; Ishida H; Ruggeri ZM
J Am Coll Cardiol; 2006 Jan; 47(1):155-62. PubMed ID: 16386680
[TBL] [Abstract][Full Text] [Related]
7. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
9. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
11. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
Hamilton SF; Miller MW; Thompson CA; Dale GL
J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
[TBL] [Abstract][Full Text] [Related]
13. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
Moser M; Bertram U; Peter K; Bode C; Ruef J
J Cardiovasc Pharmacol; 2003 Apr; 41(4):586-92. PubMed ID: 12658060
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
15. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
16. Current issues with glycoprotein IIb-IIIa antagonists.
Schneider DJ
Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
Kleiman NS
Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
[No Abstract] [Full Text] [Related]
18. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab.
Speich HE; Earhart AD; Hill SN; Cholera S; Kueter TJ; Smith JN; White MM; Jennings LK
J Thromb Haemost; 2009 Jun; 7(6):983-91. PubMed ID: 19548907
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
[TBL] [Abstract][Full Text] [Related]
20. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]